J Cosmet Dermatol. 2026 Jan;25(1):e70644. doi: 10.1111/jocd.70644.
ABSTRACT
INTRODUCTION: The global prevalence of obesity has continued to increase at alarming rates. More recently, there has been an exponential increase in the usage of GLP1 agonists in both clinically obese patients and those seeking weight loss. As a result, there has been an influx of patients who are noticing substantial weight loss and changes to their bodies. Given this surge, it is of utmost importance to have homogeneity in clinical guidelines. A consensus panel was created to discuss clinical scenarios, definitions, and set the stage for the appropriate treatment of patients who have undergone massive weight loss.
METHODS: To set standards for nonsurgical rejuvenation of patients at different ages, weight loss patterns, and genders, a consensus panel of 10 panelists was created with advanced expertise and knowledge on this patient population. Each panelist filled out a survey that addressed panelist demographics, including practice patterns and patient demographics, as well as treatment guidelines in both male and female patients. Following the survey, the panelists met to discuss preliminary results and obtain qualitative data to support their conclusions on the criteria.
RESULTS: All 10 respondents (100%) were able to complete the survey in its entirety. The panel demonstrates the need to assess and address each treatment region individually in these patients. It also emphasizes the need to consider the appropriate range of volumization based on factors such as age, gender, and the degree of weight loss. While the consensus suggests initiating biostimulator treatment concurrently with weight loss to mitigate fat pad deflation and skin laxity, uncertainties remain regarding the optimal timing and dosing.
CONCLUSION: In conclusion, this consensus panel represents the first international effort to provide clinical guidance specifically for patients experiencing medication-derived weight loss (MDWL). When creating a treatment plan for the MDWL patient, following them throughout the weight loss journey is essential to understand the more global volume changes that they may be observing.
PMID:41560373 | PMC:PMC12820441 | DOI:10.1111/jocd.70644